The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia
Open accessAbstract
BACKGROUND: The provision of sufficient basal insulin to normalize fasting plasma glucose levels may reduce cardiovascular events, but such a possibility has not been formally tested. METHODS: We randomly assigned 12,537 people (mean age, 63.5 years) with cardiovascular risk factors plus impaired fasting glucose, impaired glucose tolerance, or type 2 diabetes to receive insulin glargine (with a target fasting blood glucose level of ≤95 mg per deciliter [5.3 mmol per liter]) or standard care and to receive n-3 fatty acids or placebo with the use of a 2-by-2 factorial design. The results of the comparison between insulin glargine and standard care are reported here. The coprimary outcomes were nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes and these events plus revascularization or hospitalization for heart failure. Microvascular outcomes, incident diabetes, hypoglycemia, weight, and cancers were also compared between groups. RESULTS: The median follow-up was 6.2 years (interquartile range, 5.8 to 6.7). Rates of incident cardiovascular outcomes were similar in the insulin-glargine and standard-care groups: 2.94 and 2.85 per 100 person-years, respectively, for the first coprimary outcome (hazard ratio, 1.02; 95% confidence interval [CI], 0.94 to 1.11; P=0.63) and 5.52 and 5.28 per 100 person-years, respectively, for the second coprimary outcome (hazard ratio, 1.04; 95% CI, 0.97 to 1.11; P=0.27). New diabetes was diagnosed approximately 3 months after therapy was stopped among 30% versus 35% of 1456 participants without baseline diabetes (odds ratio, 0.80; 95% CI, 0.64 to 1.00; P=0.05). Rates of severe hypoglycemia were 1.00 versus 0.31 per 100 person-years. Median weight increased by 1.6 kg in the insulin-glargine group and fell by 0.5 kg in the standard-care group. There was no significant difference in cancers (hazard ratio, 1.00; 95% CI, 0.88 to 1.13; P=0.97). CONCLUSIONS: When used to target normal fasting plasma glucose levels for more than 6 years, insulin glargine had a neutral effect on cardiovascular outcomes and cancers. Although it reduced new-onset diabetes, insulin glargine also increased hypoglycemia and modestly increased weight. (Funded by Sanofi; ORIGIN ClinicalTrials.gov number, NCT00069784.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both insulin glargine U100 and insulin degludec have demonstrated cardiovascular safety in dedicated CVOTs (207,208).”
From Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2022) · cites this paper as [208]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“There are a number of other trials regarding cardiovascular outcomes in high-risk cohorts of patients with type 2 diabetes in which similar magnitude effects on glycemic control have been shown but without significant benefits with respect to rates of cardiovascular events or death.”
From Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (2016) · cites this paper as [16]
The cited source says what the claim attributes to it.
In the citing paper
“ORIGIN reported a 1.6 kg gain over 6 years with insulin glargine [46].”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [46]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Modest survival benefits also have been reported for breast, ovarian, endometrial, prostate, lung, kidney, liver, and earlier stage pancreatic cancers.1791–1800”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1800]
Experimental — accuracy not yet measuredIn the citing paper
“The following drug classes were excluded due to lack of current evidence of efficacy in cardiovascular outcome trials: dipeptidyl peptidase-4 inhibitors,19 sulfonylureas,20 and insulin.21,22”
From Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis (2025) · cites this paper as [21]
In the citing paper
“It is associated with a lower risk of death and HF hospitalization compared with insulin and sulphonylureas in observational studies, though dedicated randomized, controlled, CVOTs evaluating safety and efficacy of metformin have not been conducted.[555][556][557]”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [555]
In the citing paper
“It is associated with a lower risk of death and HF hospitalization compared with insulin and sulphonylureas in observational studies, though dedicated randomized, controlled, CVOTs evaluating safety and efficacy of metformin have not been conducted.[555][556][557]”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [555]
In the citing paper
“These trials have more or less uniformly demonstrated a benefit, with lifestyle more efficacious than all medications with the exception of the thiazolidinediones140–152.”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [146]
In the citing paper
“In the only RCT of insulin vs. placebo [ORIGIN, 12 537 people with CV risk factors plus impaired fasting glucose, impaired glucose tolerance, or T2DM (i.e.not in patients with HF)], insulin was not associated with higher rates of HF hospitalization than placebo.187”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [187]
In the citing paper
“Lowering glucose without addressing the vascular effects of insulin resistance may be insufficient to reduce risk of cardiovascular events.”
From The Vasculature in Prediabetes (2018) · cites this paper as [27]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
The Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
The Emerging Risk Factors Collaboration (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1008862 · Cited by 2,726
Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults
Selvin, E., Steffes, M. W., Zhu, H., Matsushita, K., Wagenknecht, L., Pankow, J., Coresh, J., & Brancati, F. L. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908359 · Cited by 1,544
Flagged first, then by citations
Research works printed but not linked: 1
- Gerstein H, 2008, Am Heart J, 155, 26
Cited by
Sorted by citations
Items 501–600 of 999
Papademetriou, V., Nylén, E., Doumas, M. N., Probstfield, J., Mann, J. F. E., Gilbert, R. E., & Gerstein, H. C. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.05.047 · Cited by 30
Precision Medicine in Obesity and Type 2 Diabetes: The Relevance of Early-Life Exposures
Estampador, A. C., & Franks, P. W. (2017) · Clinical Chemistry · doi:10.1373/clinchem.2017.273540 · Cited by 32
Pathophysiology and Prevention of Heart Disease in Diabetes Mellitus
Oktay, A. A., Aktürk, H. K., Esenboğa, K., Javed, F., Polin, N. M., & Jahangir, E. (2017) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2017.05.001 · Cited by 35
Ismail‐Beigi, F., Moghissi, E. S., Kosiborod, M., & Inzucchi, S. E. (2017) · Journal of General Internal Medicine · doi:10.1007/s11606-017-4061-7 · Cited by 28
Toh, S., Reichman, M. E., Graham, D. J., Hampp, C., Zhang, R., Butler, M. G., Iyer, A., Rucker, M., Pimentel, M., Hamilton, J., et al. (2017) · Diabetes Care · doi:10.2337/dc17-0476 · Cited by 28
Changing the Concept of Type 2 Diabetes: Beta Cell Workload Hypothesis Revisited
Saisho, Y. (2018) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530318666180821161825 · Cited by 29
Adverse Effects of Glycemia-Lowering Medications in Type 2 Diabetes
Razavi-Nematollahi, L., & Ismail‐Beigi, F. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1266-7 · Cited by 31
Gerstein, H. C., Coleman, R. L., Scott, C. A. B., Xu, S., Tuomilehto, J. O., Rydén, L., & Holman, R. R. (2020) · Diabetes Care · doi:10.2337/dc19-2046 · Cited by 28
Davidson, M. B. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109219 · Cited by 34
The ORIGIN Trial Investigators (2013) · Diabetes Care · doi:10.2337/dc12-2238 · Cited by 29
Self-citationHome, P., Dain, M., Freemantle, N., Kawamori, R., Pfohl, M., Brette, S., Pilorget, V., Scherbaum, W. A., Vespasiani, G., Vincent, M., et al. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.01.030 · Cited by 28
Drug–subphenotype interactions for cancer in type 2 diabetes mellitus
Yang, X., Lee, H. M., & Chan, J. C. N. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.37 · Cited by 27
“Mild dysglycemia” in type 2 diabetes: to be neglected or not?
Monnier, L., Colette, C., Dejager, S., & Owens, D. R. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.12.004 · Cited by 28
Diabetology and oncology meet in a network model: union is strength
Gallo, M., Gentile, L., Arvat, E., Bertetto, O., & Clemente, G. (2016) · Acta Diabetologica · doi:10.1007/s00592-016-0839-z · Cited by 28
Clemson University, C. E. S. (2006) · Oxford University Press eBooks · doi:10.1093/med/9780199543724.001.0001 · Cited by 28
Lee, T.-W., Lee, T.-I., Lin, Y.-K., Chen, Y.-C., Kao, Y.-H., & Chen, Y.-J. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03648-y · Cited by 27
Green, J. B., Everett, B. M., Ghosh, A., Younes, N., Krause-Steinrauf, H. J., Barzilay, J. I., Desouza, C. V., Inzucchi, S. E., Pokharel, Y., Schade, D. S., et al. (2024) · Circulation · doi:10.1161/circulationaha.123.066604 · Cited by 28
Bode, B. W., CHAYKIN, L. B., Sussman, A., Warren, M., Niemeyer, M., Rabøl, R., & Rodbard, H. W. (2014) · Endocrine Practice · doi:10.4158/ep13411.or · Cited by 27
Antihyperglycaemic therapies and cancer risk
Lutz, S. Z., Staiger, H., Fritsche, A., & Häring, H. (2014) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114549553 · Cited by 28
Diabetes for Cardiologists: Practical Issues in Diagnosis and Management
Mancini, G. B. J., CHENG, A. Y. Y., Connelly, K. A., FITCHETT, D. H., Goldenberg, R., Goodman, S. G., Leiter, L. A., Lonn, E., Paty, B. W., Poirier, P., et al. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.07.512 · Cited by 27
Goldenberg, R., & Berard, L. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1372118 · Cited by 27
Challenges in the management of people with diabetes and cancer
Chowdhury, T. A., & Jacob, P. (2019) · Diabetic Medicine · doi:10.1111/dme.13919 · Cited by 27
Zheng, Q., Jiang, J., Huo, Y., & Chen, D. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0930-1 · Cited by 27
Clinical pharmacology of antidiabetic drugs: What can be expected of their use?
Scheen, A. J. (2022) · La Presse Médicale · doi:10.1016/j.lpm.2022.104158 · Cited by 29
Vascular Complications of Diabetes Mellitus
Chiong, Y., & Evans‐Molina, C. (2014) · Springer eBooks · doi:10.1007/978-3-642-37078-6_49 · Cited by 28
Leong, A., Berkowitz, S. A., Triant, V. A., Porneala, B., He, W. W., Atlas, S. J., Wexler, D. J., & Meigs, J. B. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3169 · Cited by 26
Drugs for type 2 diabetes: role in the regulation of bone metabolism
Mannucci, E. (2015) · Clinical cases in mineral and bone metabolism · doi:10.11138/ccmbm/2015.12.2.130 · Cited by 23
Insulin Matters: A Practical Approach to Basal Insulin Management in Type 2 Diabetes
Berard, L., Antonishyn, N., Arcudi, K., Blunden, S., CHENG, A. Y. Y., Goldenberg, R., Harris, S. B., Jones, S., Mehan, U., Morrell, J., et al. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0375-7 · Cited by 25
Shah, D., Risebrough, N. A., Perdrizet, J. E., Iyer, N. N., Gamble, C. L., & Dang‐Tan, T. (2018) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s180067 · Cited by 25
5 Conservative treatment for PAD – Risk factor management
Frank, U., Nikol, S., & Belch, J. J. F. (2019) · VASA · doi:10.1024/0301-1526/a000835 · Cited by 27
Sanz, J., Moreno, P., & Fuster, V. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.06.045 · Cited by 27
Kong, A. P. S., Yang, X., So, W., Luk, A. O. Y., Ronald, C. W., Ozaki, R., Cheung, K. K., Lee, H. M., Yu, L. W., Xu, G., et al. (2014) · BMC Medicine · doi:10.1186/1741-7015-12-76 · Cited by 26
Russo, G. T., Giandalia, A., Romeo, E. L., Marotta, M., Alibrandi, A., Francesco, C. D., Horvath, K. V., Asztalos, B. F., & Cucinotta, D. (2014) · Journal of Endocrinological Investigation · doi:10.1007/s40618-013-0023-z · Cited by 26
Role of Insulin in the Type 2 Diabetes Therapy: Past, Present and Future
Rotella, C. M., Pala, L., & Mannucci, E. (2013) · Intern J Endocrinol Metab · doi:10.5812/ijem.7551 · Cited by 27
ter Braak, B., Siezen, C. L. E., Speksnijder, E. N., Koedoot, E., STEEG, H. V., Salvatori, D. C. F., van de Water, B., & van der Laan, J. W. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0518-y · Cited by 26
Effects of sodium glucose cotransporter type 2 inhibitors on heart failure
Nassif, M. E., & Kosiborod, M. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13678 · Cited by 26
Interpreting Adverse Signals in Diabetes Drug Development Programs
Bailey, C. J. (2013) · Diabetes Care · doi:10.2337/dc13-0182 · Cited by 25
Giorda, C. B., Picariello, R., Tartaglino, B., Marafetti, L., Noi, F. D., Alessiato, A., Costa, G., & Gnavi, R. (2015) · BMJ Open · doi:10.1136/bmjopen-2015-007959 · Cited by 25
Cammarota, S., Bruzzese, D., Catapano, A. L., Citarella, A., de Luca, L., Manzoli, L., Masulli, M., Menditto, E., Mezzetti, A., Riegler, S., et al. (2013) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2013.04.002 · Cited by 26
Kadowaki, T., Kondo, K., Sasaki, N., Miyayama, K., Yokota, S., Terata, R., & Gouda, M. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1359259 · Cited by 25
Atrial Fibrillation and Diabetes Mellitus: Dangerous Liaisons or Innocent Bystanders?
Lorenzo-Almorós, A., Casado, J., Walther, L. A. Á.-S., Méndez‐Bailón, M., & Lorenzo, Ó. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12082868 · Cited by 27
Karakasis, P., Patoulias, D., Pamporis, K., Popovic, D. S., Stachteas, P., Bougioukas, K. I., Fragakis, N., & Rizzo, M. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15259 · Cited by 25
Yang, J., Vallarino, C. R., Bron, M., Pérez, A., Liang, H., Joseph, G. L., & Yu, S. S. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.941054 · Cited by 25
Metabolic memory: mechanisms and implications for diabetic vasculopathies
Zhang, E., & Wu, Y. (2014) · Science China Life Sciences · doi:10.1007/s11427-014-4710-6 · Cited by 25
Strategies of Unloading the Failing Heart from Metabolic Stress
Koutroumpakis, E., Jozwik, B., Aguilar, D. A., & Taegtmeyer, H. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.08.035 · Cited by 26
Insulin Therapy: The Discovery That Shaped a Century
Gerstein, H. C., & Rutty, C. J. (2021) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2021.03.002 · Cited by 26
Shah, V. N., Moser, E. G., Blau, A., Dhingra, M., & Garg, S. K. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0228 · Cited by 25
Maddaloni, E., & Pozzilli, P. (2013) · Endocrine · doi:10.1007/s12020-013-0128-3 · Cited by 24
Fisiopatología y alteraciones clínicas de la diabetes mellitus tipo 2
Fernández, C. I. J., Pereira, Y. A. M., Chang, A. S. O., Olmedo, S. I. G., & Gaete, M. C. A. (2022) · Nova · doi:10.22490/24629448.6184 · Cited by 24
Hernestål-Boman, J., Norberg, M., Jansson, J., Eliasson, M., Eriksson, J. W., Lindahl, B., & Johansson, L. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-152 · Cited by 24
Safety and tolerability of glucagon-like peptide-1 receptor agonists: unresolved and emerging issues
Raccah, D. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1268598 · Cited by 24
Noman, A., Balasubramaniam, K., Alhous, M. H. A., Lee, K., Jesudason, P., Rashid, M. O., Mamas, M. A., & Zaman, A. (2016) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.26882 · Cited by 24
Alexopoulos, A., & Buse, J. B. (2019) · Metabolism · doi:10.1016/j.metabol.2019.06.012 · Cited by 25
Wilke, T., Picker, N., Mueller, S., Geier, S., Foersch, J., Aberle, J., Martin, S., Riedl, M., & Gabler, M. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s214288 · Cited by 24
Lundin, M., Ferrannini, G., Mellbin, L., Johansson, I., Norhammar, A., Näsman, P., Shahim, B., Smetana, S., Venkateshvaran, A., Wang, A., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.110141 · Cited by 25
Bonora, E., & CIGOLINI, M. (2016) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2016.03.002 · Cited by 25
Pararajasingam, G., Høfsten, D. E., Løgstrup, B. B., Egstrup, M., Henriksen, F. L., Hangaard, J., & Egstrup, K. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.03.199 · Cited by 24
What are the pharmacotherapy options for treating prediabetes?
Daniele, G., Abdul‐Ghani, M. A., & DeFronzo, R. A. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.944160 · Cited by 23
Targeting inflammation to reduce ASCVD in type 2 diabetes
Jialal, I., & Chaudhuri, A. (2018) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2018.11.001 · Cited by 23
Giorgino, F., Caruso, I., & Napoli, R. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108478 · Cited by 24
Rai, A. K., Lee, B., Gomez, R., Rajendran, D., Khan, M., & Garikipati, V. N. S. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2020.612722 · Cited by 23
Rados, D. R. V., Falcetta, M. R. R., Pinto, L. C. F., Leitão, C. B., & Gross, J. L. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108688 · Cited by 23
The ongoing evolution of basal insulin therapy over 100 years and its promise for the future
Retnakaran, R. R., & Zinman, B. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14552 · Cited by 23
Mannucci, E., Targher, G., Nreu, B., Pintaudi, B., Candido, R., Giaccari, A., Gallo, M., & Monami, M. (2022) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2022.03.007 · Cited by 23
Short‐term intensive insulin therapy at diagnosis in type 2 diabetes: plan for filling the gaps
Weng, J., Retnakaran, R. R., Ammini Ariachery, C., Ji, L., Meneghini, L., Yang, W., & Woo, J. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2603 · Cited by 25
Preventing Type 2 Diabetes Mellitus: A Call for Personalized Intervention
Glauber, H. S., & Karnieli, E. (2013) · The Permanente Journal · doi:10.7812/tpp/12-143 · Cited by 24
Price, H. I., Agnew, M. D., & Gamble, J. (2015) · BMJ Open · doi:10.1136/bmjopen-2014-006341 · Cited by 23
Udell, J. A., Scirica, B. M., Braunwald, E., Raz, I., Steg, P. G., Davidson, J. A., Hirshberg, B., & Bhatt, D. L. (2012) · Clinical Cardiology · doi:10.1002/clc.22032 · Cited by 23
Schwartz, S. S., Jellinger, P. S., & Herman, M. E. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1191955 · Cited by 24
Patel, P. A., Liang, L., Khazanie, P., Hammill, B. G., Fonarow, G. C., Yancy, C. W., Bhatt, D. L., Curtis, L. H., & Hernandez, A. F. (2016) · Circulation Heart Failure · doi:10.1161/circheartfailure.115.002638 · Cited by 23
New Long-Acting Insulin Analogs: From Clamp Studies to Clinical Practice
Bolli, G. B., & DeVries, J. H. (2015) · Diabetes Care · doi:10.2337/dc14-2314 · Cited by 22
Cardiovascular effects of anti-diabetes drugs
Younk, L. M., Lamos, E. M., & Davis, S. N. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1195368 · Cited by 23
Cardiovascular Effects of Glucose-lowering Therapies for Type 2 Diabetes: New Drugs in Perspective
Thompson, P. L., & Davis, T. M. E. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.10.008 · Cited by 23
Perspectives on cardiovascular effects of incretin-based drugs: From bedside to bench, return trip
Luconi, M., Cantini, G., Ceriello, A., & Mannucci, E. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.02.126 · Cited by 24
Chiang, C., Lin, S.-Y., Lin, T., Wang, T., Yeh, H., Chen, J., Tsai, C., Hung, Y.-J., Li, Y., Liu, P., et al. (2018) · Journal of the Chinese Medical Association · doi:10.1016/j.jcma.2018.01.001 · Cited by 22
Role of Diabetes Mellitus in Heart Failure With Preserved Ejection Fraction: A Review Article
Mgbemena, O. N., Zhang, Y., & Velarde, G. (2021) · Cureus · doi:10.7759/cureus.19398 · Cited by 23
Lin, J., Hou, J.-D., & Wu, S. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11154424 · Cited by 22
Hasebe, M., Yoshiji, S., Keidai, Y., Minamino, H., Murakami, T., Tanaka, D., Fujita, Y., Harada, N., Hamasaki, A., & Inagaki, N. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01773-z · Cited by 25
Luo, S., Zheng, X., Bao, W., Nie, S., Ding, Y., Yue, T., Zhou, Y., Hu, Y., Li, H., Yang, Q., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01854-9 · Cited by 22
Basal insulin analogs: From pathophysiology to therapy. What we see, know, and try to comprehend?
Monnier, L., Colette, C., & Owens, D. R. (2013) · Diabetes & Metabolism · doi:10.1016/j.diabet.2013.09.003 · Cited by 22
Personalizing guidelines for diabetes management: twilight or dawn of the expert?
Paschou, S. Α., & Leslie, R. D. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-161 · Cited by 22
Oikonomou, D., Kopf, S., von Bauer, R., Djuric, Z., Cebola, R., Sander, A., Englert, S., Vittas, S., Hidmark, A. S., Morcos, M., et al. (2014) · Cardiovascular Diabetology · doi:10.1186/s12933-014-0137-4 · Cited by 22
Li, J., Tong, Y., Zhang, Y., Tang, L., Lv, Q., Zhang, F., Hu, R., & Tong, N. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.12.006 · Cited by 22
Treatment of Type 2 Diabetes: From “Guidelines” to “Position Statements” and Back
Mosenzon, O., Pollack, R. M., & Raz, I. (2016) · Diabetes Care · doi:10.2337/dcs15-3003 · Cited by 24
Rahelić, D., Javor, E., Lucijanić, T., & Skelin, M. (2016) · Annals of Medicine · doi:10.1080/07853890.2016.1226514 · Cited by 23
Marine-derived n-3 fatty acids therapy for stroke
Campano, C. G. A., MacLeod, M. J., Thiès, F., Aucott, L. S., & Macleod, M. R. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012815 · Cited by 22
Antidiabetic drugs and blood pressure changes
Ilias, Ι., Thomopoulos, C., Michalopoulou, H., Bazoukis, G., Tsioufis, C. P., & Makris, T. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105108 · Cited by 22
György, J., Gaál, Z., Gerő, L., Hídvégi, T., Kempler, P., Winkler, G., & Wittmann, I. (2017) · Diabetologia Hungarica · doi:10.24121/dh.2017.1 · Cited by 23
Dermatitis due to Olindias sambaquiensis: a case report.
Kokelj, F., Mianzán, H., Avian, M., & Burnett, J. W. (1993) · PubMed · Cited by 22
Diabetes, Impaired Fasting Glucose, and Heart Failure: Its not All About the Sugar
Sharma, A., & Ezekowitz, J. A. (2014) · European Journal of Heart Failure · doi:10.1002/ejhf.179 · Cited by 22
Beyond Glucose—Rethinking Prediabetes for Precision Prevention
Wagner, R. J., Selvin, E., Sehgal, R., Prystupa, K., Misra, S., Fritsche, A., & Heni, M. (2025) · Diabetes Care · doi:10.2337/dci25-0054 · Cited by 23
Cherukuri, L., Smith, M. S., & Tayek, J. A. (2018) · doi:10.31038/edmj.2018232 · Cited by 21
Tratamento farmacológico da hiperglicemia no DM2
Filho, R. L. D. S., Albuquerque, L., Cavalcanti, S. M., Tambascia, M. A., Valente, F., & Bertoluci, M. C. (2022) · Conectando Pessoas eBooks · doi:10.29327/557753.2022-10 · Cited by 33
Park, C. S., Choi, E., Kyung-DoHan, Yoo, J., Ahn, H., Kwon, S., Lee, S., Oh, S., & Lip, G. Y. H. (2022) · Diabetes Care · doi:10.2337/dc22-1655 · Cited by 21
Jayedi, A., Soltani, S., Emadi, A., Ghods, K., & Shab‐Bidar, S. (2023) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2023.2251583 · Cited by 23
Sheikh, I. M., Hassan, O. A., Adam, S. M., Ali, A. I., Ogedegbe, O. J., Tabowei, G., Barbarawi, A., Yussuf, F. M., & Nor, M. A. (2023) · Cureus · doi:10.7759/cureus.46911 · Cited by 28
Diabetes and cancer relationships (糖尿病与肿瘤的关联性)
Wang, T., Ning, G., & Bloomgarden, Z. T. (2013) · Journal of Diabetes · doi:10.1111/1753-0407.12057 · Cited by 21
Long-term insulin glargine therapy in type 2 diabetes mellitus: a focus on cardiovascular outcomes
Donner, T. W., & Joseph, J. J. (2015) · Vascular Health and Risk Management · doi:10.2147/vhrm.s50286 · Cited by 21
Type 2 Diabetes Mellitus, Oral Diabetic Medications, Insulin Therapy, and Overall Breast Cancer Risk
Ahmadieh, H., & Azar, S. T. (2013) · ISRN Endocrinology · doi:10.1155/2013/181240 · Cited by 21
Cardiovascular risks in type 2 diabetes and the interpretation of cardiovascular outcome trials
Hinnen, D. A., & Kruger, D. F. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s188705 · Cited by 23
Metadata
- Authors
- The ORIGIN Trial Investigators
- Affiliations
- Population Health Research Institute (CA)
- Corresponding author
- The ORIGIN Trial Investigators
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-07-26
- Volume
- 367
- Issue
- 4
- Pages
- 319-328
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1975663485
- Semantic Scholar
- 695c6a8e398d66ae418b143a3491ad91d28443bb
- Cited by
- 1,636
- References
- 29
- Citations by year
- 2026: 34 · 2025: 41 · 2024: 76 · 2023: 86 · 2022: 82 · 2021: 108 · 2020: 101 · 2019: 139 · 2018: 155 · 2017: 152 · 2016: 155 · 2015: 132 · 2014: 168 · 2013: 147 · 2012: 53
- FWCI
- 128.26
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Monash University Research Portal (Monash University) (acceptedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- HAL (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- IRIS (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- University of Oxford
- AFA Försäkring
- Hjärt-Lungfonden
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- basal insulin, insulin glargine, impaired fasting glucose, impaired glucose tolerance, type 2 diabetes, cardiovascular outcomes, myocardial infarction, stroke, heart failure, omega-3 fatty acids, hypoglycemia, weight gain, cancer risk, microvascular outcomes, cardiovascular risk factors, revascularization, hospitalization, new-onset diabetes
- MeSH terms
- Insulin Glargine, Aged, Blood Glucose, Cardiovascular Diseases, Cholesterol, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Therapy, Combination, Fasting, Female, Follow-Up Studies, Hospitalization, Humans, Hypoglycemia, Hypoglycemic Agents, Male, Middle Aged, Triglycerides, Fatty Acids, Omega-3, Incidence, Proportional Hazards Models, Glucose Intolerance, Insulin, Long-Acting, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
